Enhancing Growth Monitoring Visits Through Health Workers Training on Growth Monitoring and Promotion, GMP Guideline a Community Health Volunteer Mobilization for Increasing Demand of GMP Through GMP Day in Joshipur Rural Municipality, Kailai, Nepal

The goal of this clinical trial is to learn if health workers training on growth promotion and monitoring guideline and Female Community Health Volunteers mobilization for increasing demand for growth monitoring and promotion, GMP through growth monitoring and promotion day, GMP day) can enhance the growth monitoring and promotion practices in mothers and caretaker having under two years children. The main questions it aims to answer are:
* Does health workers training on GMP guideline enhances the growth monitoring and promotion practices in mothers and caretakers having under two years children?
* Does FCHV mobilization enhances growth monitoring and promotion practices in mothers and caretakers having under two years children? Participants will
* Health workers of the Joshipur rural municipality will have to attend Training session on GMP guideline,
* Mothers and caretakers having under two years children will have to visit to the nearest health facility for GMP visits for their children

开始日期2024-12-01

申办/合作机构

Kathmandu University

NCT06431581

/ RecruitingN/AIIT

Effect of a Mobile Health Intervention on Birth Outcome and Infant Health in a Tertiary Healthcare Facility in Nepal

Globally, neonatal and infant mortality persist as challenging concerns, paralleled by a notable prevalence of low birth weight, preterm birth, and challenges in child growth and development. Some of the factors contributing to these issues include poor maternal health and nutrition, maternal smoking, and insufficient maternal awareness. Despite global efforts to improve maternal, newborn, and child health, adverse birth outcomes remain significant challenges, particularly in low and middle-income countries (LMICs). A noteworthy observation is that not all pregnant women modify their behaviors for their and their baby's health due to lack of social support, fear and insecurity. Recognizing the potential for interventions during pregnancy to positively influence maternal, fetal, and neonatal health, this research underscores the role of Mobile Health (mHealth) technologies in leveraging information and communication technology for health service delivery.
Accordingly, the study aims to evaluate the effect of mobile health intervention on birth outcomes and infant health in Nepal. In the initial phase, a qualitative study will be conducted to explore the enablers and barriers of perinatal care and preferences of pregnant women through focus group discussions. These insights will inform the development of user-centered educational videos and tailored m-Health interventions for pregnant women.
A two-arm parallel randomized controlled trial will then assess the m-Health intervention's effect on the birth outcomes and infant health of the pregnant women attending the antenatal care clinic of Dhulikhel Hospital. The investigaotors will randomize pregnant women at gestational age 14-22 weeks into either a control group (who will receive standard care along with a control video and reminder phone call for follow-up) or an intervention group (who will receive standard care along with m-health intervention that includes educational video, short message service (SMS) and reminder phone call for follow up).
Follow-up will be done from enrollment until the child reaches one year of age, with a focus on evaluating effect of m-Health intervention on birth outcomes (birth weight and gestational age at delivery) and infant health (growth and development of the infant). Data collection will utilize a self-constructed semi-structured questionnaire, along with validated questionnaires. The collected data will be analyzed using STATA 14, contributing valuable insights into the potential effect of m-Health intervention on birth outcomes and infant health.

开始日期2024-09-09

申办/合作机构

Kathmandu University

NCT06444100

/ Not yet recruitingN/AIIT

Predictors of Child Abuse Among School Going Children and Impact of Structural Training on Child Abuse Among School Teachers of Dhulikhel Municipality

Child abuse stands as a global public health crisis, impeding the natural growth and development of children. The repercussions of abuse extend beyond immediate trauma, resulting in heightened medical costs and enduring health consequences that may persist into adulthood. These consequences encompass a spectrum of issues, including attachment disorders, behavioral abnormalities, depression, post-traumatic stress disorder, altered neurobiological structures, suicidal ideation, risky sexual practices, and susceptibility to sexually transmitted infections. The detrimental impact of any form of child abuse lingers into the adult lives of affected individuals.
This study aims to determine the Predictors of Child Abuse among School Going Children and the Impact of Structural Training on Child Abuse Among School Teachers of Dhulikhel Municipality in selected schools of Dhulikhel Municipality. Employing descriptive-analytical, true-experimental, and qualitative research designs, the study involves children aged ≥ 11 and teachers across diverse schools. A purposeful sample technique will be used to select teachers to explore school teachers' strategies in supporting students experiencing childhood violence. A simple stratified sampling technique will be used to select schools and a simple random sampling technique will be used to select the required number of students. Subsequently, one group of teachers undergoes comprehensive training on child protection recognition and response, while another does not. Following a two-week intervention, Investigators will conduct a posttest to evaluate teachers' knowledge and attitudes. To ensure clarity, both standard and self-constructed research tools will be translated into Nepali. Subsequently, these tools will be employed for data collection. The gathered information will be entered into an Excel datasheet and later transferred to Stata version 13 for a comprehensive analysis involving both descriptive and inferential statistics.

开始日期2024-06-15

申办/合作机构

Kathmandu University

100 项与 Kathmandu University 相关的临床结果

登录后查看更多信息

0 项与 Kathmandu University 相关的专利（医药）

登录后查看更多信息

2,741

项与 Kathmandu University 相关的文献（医药）

2025-12-31·Cogent Education

Exploring the dis/empowering cultures in prospective science learning: nurturing transformative learning

作者: Luitel, Bal Chandra ; Thapaliya, Pratima

2025-12-31·International Journal of Adolescence and Youth

Factors affecting adolescent and youth girls’ empowerment: a survey of selected areas of Rupandehi District

作者: Pande, Suman ; Bhattarai, Prakash C. ; Gautam, Suresh

2025-07-01·American Journal of Ophthalmology

Epidemiologic Study of Pediatric Uveitis and its Ophthalmic Complications Using the Korean National Health Insurance Claim Database

Article

作者: Bromeo, Albert John ; Do, Diana ; Hong, Eun Hee ; Akhavanrezayat, Amir ; Tran, Anh Ngoc Tram ; Khatri, Anadi ; Karaca, Irmak ; Thng, Zheng Xian ; Park, Sung Who ; Shin, Yong Un ; Kang, Min Ho ; Nguyen, Quan Dong ; Or, Chi Mong Christopher ; Kim, Jiyeong

PURPOSETo investigate the incidence and ophthalmic complications of pediatric uveitis using the Korean National Health Insurance (NHI) Service database.DESIGNNationwide population-based longitudinal cohort study.METHODSThis study used the NHI database from 2005 to 2021 and included individuals <18 years of age diagnosed with uveitis on at least three separate visits between 2010 and 2014, with a five-year wash-out period and a seven-year follow-up period. All uveitis cases were classified as either anterior or nonanterior on the basis of the diagnostic code. The occurrence of ophthalmic complications during the follow-up period, and the systemic and socioeconomic associations between pediatric uveitis and its ophthalmic complications were investigated. We obtained the incidence of total, anterior, and nonanterior pediatric uveitis between 2010 and 2014; the percentage of ophthalmic complications during the follow-up period; and hazard ratios for ophthalmic complications of anterior and nonanterior uveitis.RESULTSA total of 9495 cases of pediatric uveitis (8734 cases with anterior and 761 with nonanterior uveitis) were identified, with an average annual incidence (per 10 000 children) of total, anterior, and nonanterior uveitis being 2.0, 1.8, and 0.2, respectively. The most common complications were glaucoma or presumed ocular hypertension, macular disease, and amblyopia. Patients with nonanterior uveitis had a significantly higher risk of ophthalmic complications including retinal detachment, cataract, amblyopia, and glaucoma or presumed ocular hypertension than those with anterior uveitis.CONCLUSIONSThis nationwide analysis of pediatric uveitis in South Korea revealed an average incidence of 2.0 per 10 000 children, highlighting the higher risks of ophthalmic complications associated with nonanterior uveitis.

项与 Kathmandu University 相关的新闻（医药）

2022-08-01

·GlobeNewswire-Health Care

RS Biotherapeutics Appoints Jeremy Plumb as Chief Cultivation Officer

Supports the company’s plans to build a biotherapeutics cultivation and manufacturing site in Cumberland, MarylandCUMBERLAND, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that it has appointed Jeremy Plumb as its Chief Cultivation Officer. Mr. Plumb will play an integral role in the company’s plans to develop a biotherapeutics cultivation and manufacturing site in the Cumberland, Maryland area, which could potentially generate 100 high paying jobs within the next five years. Prior to joining RS BioTherapeutics, Mr. Plumb served as the Director of Production Science at Groundworks Industries, one of the largest Oregon-owned and operated cannabis companies, as well as its portfolio brand, Prūf Cultivar, which operates one of the most technologically advanced controlled environment agriculture (CEA) cultivation facilities in North America. At Prūf, Jeremy combined his decades of cannabis horticulture experience with cutting-edge technology to deliver previously unattainable consistency in product quality. Mr. Plumb has also served as a cannabis consultant to Israel medical cannabis researchers and as a cannabis policy advisor for members of the U.S. Congress. He also serves on the Oregon Liquor Control Commission’s rule-making advisory committee, is a founding member of Smart Cannabis, and serves on the technical advisory committee of the Resource Innovation Institute. In addition, he is a board member of the MCRC (Multidimensional Cannabis Research Center) based at Kathmandu University and serves as an advisory board member of Node Labs, a botanical tissue culture company based in San Francisco, California. Mr. Plumb holds a Bachelor of Arts in Ecology from the New College of California and a Master of Arts in Psychology from the Pacific Graduate Institute. Commenting on the appointment, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, “We are honored to welcome Jeremy Plumb to our talented leadership team. Jeremy is one of the most well-respected CEA cultivators in the world and will play a vital role in helping RS BioTherapeutics establish and scale our cultivation and manufacturing operation to support the development of our first investigational compound, RSBT-001 as well as other endocannabinoid system-focused therapeutics.” Jeremy Plumb said, “I am very excited to join the RS BioTherapeutics team and support the research, development, and commercialization of forward-thinking endocannabinoid system-focused interventions to address chronic and acute pulmonary inflammation-based diseases. I have long advocated for therapies focused upon the endocannabinoid system and have dedicated my work to understanding phenotypic plasticity and what it takes to support the most useful therapeutic profiles.” About RS BioTherapeutics Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC. The company’s mission is to harness its strong and thorough understanding of the Endocannabinoid System in the research, development, and commercialization of forward-thinking interventions to address chronic and acute pulmonary inflammation-based diseases. More information on RS Biotherapeutics can be found at www.rsbiotherapeutics.com. Media Contact: David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com

100 项与 Kathmandu University 相关的药物交易

登录后查看更多信息

100 项与 Kathmandu University 相关的转化医学

登录后查看更多信息